# Progranulin’s Protective Mechanisms and Therapeutic Potential in Cardiovascular Disease

**Authors:** Gan Qiao, Yongxiang Lu, Jianping Wu, Chunyang Ren, Roudian Lin, Chunxiang Zhang

PMC · DOI: 10.3390/cells14110762 · 2025-05-22

## TL;DR

This paper explores how progranulin protects the heart and blood vessels, suggesting it could be a new treatment for cardiovascular disease.

## Contribution

The paper reviews progranulin’s novel protective mechanisms and therapeutic potential in cardiovascular disease.

## Key findings

- Progranulin modulates inflammatory pathways and enhances mitochondrial function to protect cardiovascular health.
- It engages signaling pathways like PI3K/Akt and Wnt/β-catenin to reduce oxidative stress and aid cardiac repair.
- Progranulin influences lipid metabolism and vascular smooth muscle cell behavior, impacting atherogenesis and vascular homeostasis.

## Abstract

Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality globally, prompting the investigation of novel therapeutic targets. Progranulin (PGRN), a glycoprotein initially associated with neurodegenerative disorders, has emerged as a critical protective agent in cardiovascular health. Recent studies indicate that PGRN exerts its protective effects through various mechanisms, including the modulation of inflammatory pathways, enhancement of mitochondrial function, and promotion of vascular integrity. By engaging with key signaling pathways, such as PI3K/Akt, NF-κB and Wnt/β-catenin, PGRN mitigates oxidative stress and fosters an environment conducive to cardiac repair following ischemic injury. Furthermore, PGRN’s role in lipid metabolism and vascular smooth muscle cell behavior highlights its complexity in influencing atherogenesis and vascular homeostasis. This review synthesizes current knowledge regarding PGRN’s protective mechanisms in CVD, emphasizing its potential as a therapeutic target and paving the way for innovative approaches to prevent and treat cardiovascular diseases, ultimately improving patient outcomes in this critical area of public health.

## Linked entities

- **Proteins:** grn.L (granulin L homeolog), GRN (granulin precursor)
- **Diseases:** Cardiovascular disease (MONDO:0004995)

## Full-text entities

- **Genes:** PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, GRN (granulin precursor) [NCBI Gene 2896] {aka CLN11, FTD2, GEP, GP88, PCDGF, PEPI}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}
- **Diseases:** inflammatory (MESH:D007249), ischemic injury (MESH:D017202), CVD (MESH:D002318), neurodegenerative disorders (MESH:D019636), atherogenesis (MESH:D050197)
- **Chemicals:** lipid (MESH:D008055)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12153738/full.md

---
Source: https://tomesphere.com/paper/PMC12153738